Kyverna Therapeutics Announces Leadership Update, Warner Biddle Appointed As Chief Executive Officer, Succeeds Peter Maag, Who Has Resigned From His Role As Ceo And A Member Of The Board, Effective Immediately
Kyverna Therapeutics Announces Leadership Update, Warner Biddle Appointed As Chief Executive Officer, Succeeds Peter Maag, Who Has Resigned From His Role As Ceo And A Member Of The Board, Effective Immediately
EMERYVILLE, Calif., Sept. 16, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of Warner Biddle as the Company's Chief Executive Officer (CEO) and a member of its Board of Directors. Mr. Biddle succeeds Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately. In addition, Kyverna announced the appointment of Christi Shaw to its Board of Directors. Ms. Shaw succeeds Brian Kotzin, M.D., who has decided to step down from the Board of Directors.– Warner Biddle Appointed as Chief Executive Officer and to Board of Directors, Bringing Over 30 Years of Commercial, Product Planning and Franchise Leadership Experience, Including Successful Launches for CAR T Pioneer in Hematology
— 华纳·比德尔被任命为首席执行官和董事会成员，拥有超过30年的商业、产品规划和特许经营领导经验，包括成功推出CAR t血液学先锋
– Christi Shaw, Life Sciences Leader at Multiple Major Pharmaceutical and Biotech Companies and Across Therapeutic Areas, Appointed to Board of Directors
— 多家主要制药和生物技术公司以及治疗领域的生命科学负责人克里斯蒂·肖被任命为董事会成员
– Together Strengthen Leadership as Trailblazers of Cell Therapy with Extensive Experience Leading Through Clinical Development, Manufacturing, Commercial Launch and Expansion
— 共同加强作为细胞疗法开拓者的领导地位，在临床开发、制造、商业发布和扩张方面拥有丰富的经验
EMERYVILLE, Calif., Sept. 16, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the appointment of Warner Biddle as the Company's Chief Executive Officer (CEO) and a member of its Board of Directors. Mr. Biddle succeeds Peter Maag, Ph.D., who has resigned from his role as CEO and a member of the Board, effective immediately. In addition, Kyverna announced the appointment of Christi Shaw to its Board of Directors. Ms. Shaw succeeds Brian Kotzin, M.D., who has decided to step down from the Board of Directors.
加利福尼亚州埃默里维尔，2024年9月16日 /PRNewswire/ — Kyverna Therapeutics, Inc.（Kyverna）是一家以患者为中心的临床阶段生物制药公司，专注于为自身免疫性疾病患者开发细胞疗法，今天宣布任命华纳·比德尔为公司首席执行官（CEO）兼董事会成员。比德尔先生接替彼得·马格博士，后者已辞去首席执行官和董事会成员的职务，立即生效。此外，Kyverna宣布任命克里斯蒂·肖为董事会成员。肖女士接替了决定辞去董事会职务的布莱恩·科津万博士。
